SDRIFE und bullöse Reaktion nach Behandlung mit Enfortumab Vedotin plus Pembrolizumab: Fallserie-Reference-Cited by-同舟云学术

SDRIFE und bullöse Reaktion nach Behandlung mit Enfortumab Vedotin plus Pembrolizumab: Fallserie

Published:2024-08 Issue:8 Volume:22 Page:1161-1165
ISSN:1610-0379
Container-title:JDDG: Journal der Deutschen Dermatologischen Gesellschaft
language:et
Short-container-title:J Deutsche Derma Gesell

Author:

Lluch‐Galcerá Juan J.¹^ORCID,Manzanares‐Oliver Nerea²,Martinez‐Molina Manel¹^ORCID,Valdivieso Lorena³,Boada Aram¹^ORCID,Segura Sònia²^ORCID,Rovira Roger²,Pujol Ramón M²,Jaka Ane¹^ORCID

Affiliation:

1. Department of Dermatology Hospital Universitari Germans Trials i Pujol Institut d'Investigació GermansTrias i Pujol Universitat Autònoma de Barcelona Departament de Medicina Badalona Barcelona Spain

2. Department of Dermatology Hospital del Mar Institut Mar d'Investigacions Mèdiques Universitat Autònoma de Barcelona (UAB) and Universitat Pompeu Fabra (UPF) Barcelona Spain

3. Department of Pathology Hospital Universitari Germans Trias i Pujol Badalona Barcelona Spain

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ddg.15453_g

Reference9 articles.

1. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin

2. Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin

3. Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma

4. Cutaneous reactions with enfortumab vedotin: A case series and review of the literature

5. World Health Organization.Vigiaccess.org [Internet]. Available from:https://www.vigiaccess.org[Last accessed January 24 2024].